Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Merus
(NASDAQ:MRUS)
Intraday
$41.05
0.74
[1.84%]
After-Hours
$41.05
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$41.05
0.74
[1.84%]
At close: Apr 17
$41.05
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Merus Stock (NASDAQ:MRUS)
Merus Stock (NASDAQ: MRUS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 11, 2024
Needham Reiterates Buy on Merus, Maintains $66 Price Target
Benzinga Newsdesk
-
6 days ago
Monday, April 08, 2024
Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024
Benzinga Newsdesk
-
Apr 8, 2024, 12:03PM
Thursday, March 28, 2024
Truist Securities Initiates Coverage On Merus with Buy Rating, Announces Price Target of $69
Benzinga Newsdesk
-
Mar 28, 2024, 11:34AM
Thursday, March 07, 2024
Needham Maintains Buy on Merus, Raises Price Target to $66
Benzinga Newsdesk
-
Mar 7, 2024, 6:06AM
Wednesday, March 06, 2024
Gilead and Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers; Merus To Receive Upfront Cash Payment Of $56M For Initial Targets And Equity Investment By Gilead Of $25M in Merus Common Shares, Merus Is Also Eligible to Receive Up to $1.5B
Benzinga Newsdesk
-
Mar 6, 2024, 8:05AM
Tuesday, March 05, 2024
Merus Announces Publication Of Abstract For Presentation At AACR Annual Meeting 2024
Benzinga Newsdesk
-
Mar 5, 2024, 4:31PM
Monday, March 04, 2024
Needham Maintains Buy on Merus, Raises Price Target to $65
Benzinga Newsdesk
-
Mar 4, 2024, 5:35AM
Thursday, February 29, 2024
On Wednesday February 28, 2024, Merus Reported Q4 Adjusted. EPS $(1.09) Misses $(0.74) Estimate, Sales $8.94M Miss $10.13M Estimate
Happy Mohamed
-
Feb 29, 2024, 3:26PM
HC Wainwright & Co. Maintains Buy on Merus, Raises Price Target to $65
Benzinga Newsdesk
-
Feb 29, 2024, 3:24PM
Stifel Maintains Buy on Merus, Raises Price Target to $65
Benzinga Newsdesk
-
Feb 29, 2024, 12:43PM
BMO Capital Maintains Outperform on Merus, Raises Price Target to $58
Benzinga Newsdesk
-
Feb 29, 2024, 8:08AM
Wednesday, February 28, 2024
As Of December 31, 2023, Merus Had $411.7M Cash, Cash Equivalents And Marketable Securities
Benzinga Newsdesk
-
Feb 28, 2024, 5:04PM
Monday, December 04, 2023
Needham Reiterates Buy on Merus, Maintains $42 Price Target
Benzinga Newsdesk
-
Dec 4, 2023, 6:42AM
Merus Presented Updated Clinical Data On MCLA-129 For Cancer Treatment At ESMO Asia 2023
Benzinga Newsdesk
-
Dec 4, 2023, 1:56AM
Tuesday, November 28, 2023
Expert Ratings for Merus
Benzinga Insights
-
Nov 28, 2023, 7:00AM
Needham Reiterates Buy on Merus, Maintains $42 Price Target
Benzinga Newsdesk
-
Nov 28, 2023, 5:19AM
Monday, November 27, 2023
Merus Announces Publication Of Abstracts On MCLA-129 For Presentation At ESMO Asia Congress 2023
Benzinga Newsdesk
-
Nov 26, 2023, 11:44PM
Thursday, November 02, 2023
Merus Q3 EPS $(0.43) Beats $(0.75) Estimate, Sales $11.03M Beat $10.38M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 5:29PM
Canaccord Genuity Initiates Coverage On Merus with Buy Rating, Announces Price Target of $45
Benzinga Newsdesk
-
Nov 2, 2023, 6:07AM
Tuesday, October 24, 2023
The Latest Analyst Ratings for Merus
Benzinga Insights
-
Oct 24, 2023, 3:00PM
Stifel Maintains Buy on Merus, Lowers Price Target to $40
Benzinga Newsdesk
-
Oct 24, 2023, 1:16PM
Monday, October 23, 2023
Merus N.V. Announces Interim Clinical Data From Phase 1/2 eNRGy Trial And Early Access Program Of Zeno
Benzinga Newsdesk
-
Oct 23, 2023, 7:33AM
Monday, October 16, 2023
Reported Late Sunday, Merus Published Two Abstracts Highlighting Updated Interim Clinical Data From The Ongoing Phase 1/2 Enrgy Trial And Early Access Program Of The Bispecific Antibody Zenocutuzumab In Patients With Neuregulin 1 Fusion Cancer
Benzinga Newsdesk
-
Oct 16, 2023, 3:32AM
Friday, October 06, 2023
Merus Announces Abstracts Accepted For Presentation At The ESMO Asia Congress 2023
Benzinga Newsdesk
-
Oct 6, 2023, 9:33AM
Thursday, September 14, 2023
10 Analysts Have This to Say About Merus
Benzinga Insights
-
Sep 14, 2023, 10:00AM
Needham Reiterates Buy on Merus, Maintains $45 Price Target
Benzinga Newsdesk
-
Sep 14, 2023, 6:03AM
Monday, September 11, 2023
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
Vandana Singh
-
Sep 11, 2023, 2:31PM
Monday, August 21, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
Benzinga Insights
-
Aug 21, 2023, 11:00AM
TD Cowen Initiates Coverage On Merus with Outperform Rating
Benzinga Newsdesk
-
Aug 21, 2023, 7:01AM
Thursday, August 10, 2023
Where Merus Stands With Analysts
Benzinga Insights
-
Aug 10, 2023, 12:00PM
Citigroup Maintains Buy on Merus, Lowers Price Target to $46
Benzinga Newsdesk
-
Aug 10, 2023, 11:56AM
Merus Announces Pricing Of $150M Public Offering Of 6,818,182 Common Shares At $22/Share
Benzinga Newsdesk
-
Aug 10, 2023, 3:01AM
Wednesday, August 09, 2023
Merus N.V. Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Benzinga Newsdesk
-
Aug 9, 2023, 4:44PM
Tuesday, August 08, 2023
Merus shares are trading lower after the company reported a year-over-year decrease in Q2 financial results.
Benzinga Newsdesk
-
Aug 8, 2023, 1:20PM
Guggenheim Maintains Buy on Merus, Raises Price Target to $48
Benzinga Newsdesk
-
Aug 8, 2023, 12:51PM
Stifel Maintains Buy on Merus, Raises Price Target to $45
Benzinga Newsdesk
-
Aug 8, 2023, 11:04AM
EF Hutton Reiterates Buy on Merus, Maintains $35 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 7:44AM
HC Wainwright & Co. Reiterates Buy on Merus, Maintains $48 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 6:35AM
Needham Reiterates Buy on Merus, Maintains $45 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 5:32AM
Monday, August 07, 2023
Merus Q2 EPS $(0.66) Down From $(0.13) YoY, Sales $10.48M Down From $12.68M YoY
Benzinga Newsdesk
-
Aug 7, 2023, 5:04PM
Friday, July 28, 2023
Merus Announces Two Clinical Abstracts On Zenocutuzumab In Nrg1-Fusion Non-Small Cell Lung Cancer And Pancreatic Cancer Selected For Presentation At The Esmo Congress 2023
Benzinga Newsdesk
-
Jul 28, 2023, 8:08AM
Monday, July 24, 2023
Expert Ratings for Merus
Benzinga Insights
-
Jul 24, 2023, 9:00AM
Needham Reiterates Buy on Merus, Maintains $45 Price Target
Benzinga Newsdesk
-
Jul 24, 2023, 5:50AM
Tuesday, July 18, 2023
EF Hutton Reiterates Buy on Merus, Maintains $35 Price Target
Benzinga Newsdesk
-
Jul 18, 2023, 4:10AM
Wednesday, July 05, 2023
Merus N.V. Announces Zenocutuzumab Granted Second Breakthrough Therapy Designation By The U.S. Food & Drug Administration
Happy Mohamed
-
Jul 5, 2023, 4:03PM
Friday, June 30, 2023
Analyst Expectations for Merus's Future
Benzinga Insights
-
Jun 30, 2023, 12:00PM
Needham Reiterates Buy on Merus, Maintains $46 Price Target
Benzinga Newsdesk
-
Jun 30, 2023, 6:10AM
Thursday, June 29, 2023
Merus shares are trading higher after the FDA granted Breakthrough Therapy Designation to zenocutuzumab for the treatment of NRG1+ pancreatic cancer.
Benzinga Newsdesk
-
Jun 29, 2023, 4:32PM
Merus Announces Zenocutuzumab Has Been Granted Breakthrough Therapy Designation By The FDA For NRG1+ Pancreatic Cancer
Benzinga Newsdesk
-
Jun 29, 2023, 4:30PM
Thursday, June 15, 2023
Merus Appoints Life Sciences Strategic And Financial Industry Veteran Greg Perry As Chief Financial Officer
Benzinga Newsdesk
-
Jun 15, 2023, 8:04AM
Show more